found that the combination of pazopanib and metformin effectively inhibits tumor cell proliferation by suppressing signaling pathways such as phosphorylated Akt/ nuclear factor kappa‐light‐chain‐enhancer of activated B cells/ signal transducer and activator of transcription 3 (p‐Akt/NF‐κB/IL‐6/STAT3) and hypoxia‐inducible factor 1‐alpha/ vascular endothelial growth factor/ (HIF1α/VEGF), thereby reducing the activity levels of Akt and NF‐κB, decreasing Interleukin‐6 (IL‐6) secretion, and inhibiting STAT3 signal transduction, which collectively weakens the pro‐inflammatory microenvironment. Here, STAT3 is linked to neoplasm.